J Yeungnam Med Sci.  2023 Nov;40(Suppl):S73-S80. 10.12701/jyms.2023.00528.

Performance evaluation of Barozen Lipid Plus for point-of-care testing of lipid profiles: a method comparison study

• Yu S
• Sun HY
• Yoo B

• KMID: 2548345
• DOI: http://doi.org/10.12701/jyms.2023.00528

Abstract

Background
The quick and easy nature of point-of-care (POC) testing devices allows regular monitoring of serum lipid levels to increase efficiency. The purpose of this study was to assess a POC lipid analyzer, Barozen Lipid Plus (MICO Biomed Co., Ltd.), which uses capillary blood to measure total cholesterol (TC), triglycerides (TGs), and high-density lipoprotein cholesterol (HDL-C).
Methods
Capillary and venous blood samples were collected from 110 participants at a single center in Korea between June 10 and June 26, 2021. TC, TG, and HDL-C measurements using Barozen Lipid Plus were compared with measurements using our reference device, the Roche-Hitachi Cobas 8000 c702 (Hitachi High-Technologies Corporation). This study followed the guidelines of the Clinical and Laboratory Standards Institute and the Clinical Laboratory Improvement Amendments. We surveyed participants regarding the convenience of the POC device using a questionnaire following the completion of blood collection.
Results
When compared to the reference equipment, the measurements obtained using Barozen Lipid Plus were more than 95% satisfactory within TC±10%, TG±25%, and HDL-C±30%. The coefficient of variation in the repeatability testing was within 5% for TC, 5% for TGs, and 7% for HDL-C. The survey results indicated high levels of satisfaction. No adverse events were reported.
Conclusion
These findings suggest that Barozen Lipid Plus is reliable for measuring lipid profiles and can therefore be used to monitor lipid levels at the time and place of patient care.

Keyword

Point-of-care testing; Lipids; Cholesterol; Triglycerides; Dyslipidemias

Figure

• 

  Fig. 1. Passing-Bablock regression analysis of the correlation between Barozen Lipid Plus (MICO Biomed Co., Ltd. Seongnam, Korea) and Roche-Hitachi Cobas 8000 c702 (Hitachi High-Technologies Corporation, Tokyo, Japan) for (A) total cholesterol (TC), (B) triglycerides, and (C) high-density lipoprotein (HDL) cholesterol.

Reference

References

1. Durrington P. Dyslipidaemia. Lancet. 2003; 362:717–31.

2. World Health Organization (WHO). The global health observatory: raised cholesterol [Internet]. Geneva: WHO;2008. [cited 2023 May 24]. https://www.who.int/data/gho/indicator-metadata-registry/imr-details/3236.

3. Olesen SS, Harakow A, Krogh K, Drewes AM, Handberg A, Christensen PA. Hypertriglyceridemia is often under recognized as an aetiologic risk factor for acute pancreatitis: a population-based cohort study. Pancreatology. 2021; 21:334–41.

4. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 2007; 298:776–85.

5. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302:1993–2000.

6. Ministry of Health and Welfare, Korea Centers for Disease Control and Prevention. Korea Health Statistics 2019: Korea National Health and Nutrition Examination Survey (KNHANES VIII-1) [Internet]. Cheongju: Korea Centers for Disease Control and Prevention; 2020 [cited 2023 May 24]. https://knhanes.kdca.go.kr/knhanes/sub04/sub04_04_01.do.

7. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019; 140:e596–646.

8. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2019; 73:e285–350.

9. Clinical and Laboratory Standards Institute (CLSI). EP09: Measurement procedure comparison and bias estimation using patient samples. 3rd ed. Wayne, PA: CLSI;2018.

10. International Organization for Standardization (ISO). ISO 17511:2020 In vitro diagnostic medical devices: requirements for establishing metrological traceability of values assigned to calibrators, trueness control materials and human samples. 2nd ed. Geneva: ISO;2020.

11. Kim SY, Jeong TD, Lee W, Chun S, Min WK. Performance evaluation of the Roche-Hitachi Cobas 8000 c702 chemistry autoanalyzer. Lab Med Online. 2014; 4:132–9.

12. Clinical and Laboratory Standards Institute (CLSI). EP05-A3: Evaluation of precision of quantitative measurement procedures. 3rd ed. Wayne, PA: CLSI;2014.

13. Clinical and Laboratory Standards Institute (CLSI). EP09-A3: Measurement procedure comparison and bias estimation using patient samples; approved guideline. Wayne, PA: CLSI;2013.

14. Clinical and Laboratory Standards Institute (CLSI). EP07: Interference testing in clinical chemistry. Wayne, PA: CLSI;2018.

15. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38:2459–72.

16. Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019; 321:364–73.

17. Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, et al. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012; 307:2499–506.

18. Andrews J, Janssan A, Nguyen T, Pisaniello AD, Scherer DJ, Kastelein JJ, et al. Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. Cardiovasc Diagn Ther. 2017; 7:45–51.

19. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41:111–88.

20. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019; 139:e1082–143.

21. JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart. 2014; 100(Suppl 2):ii1–67.

22. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010; 375:1634–9.

23. Lindkvist B, Appelros S, Regnér S, Manjer J. A prospective cohort study on risk of acute pancreatitis related to serum triglycerides, cholesterol and fasting glucose. Pancreatology. 2012; 12:317–24.

24. Glasziou PP, Irwig L, Kirby AC, Tonkin AM, Simes RJ. Which lipid measurement should we monitor? An analysis of the LIPID study. BMJ Open. 2014; 4:e003512.

25. Bolodeoku J. Self-monitoring blood cholesterol (SMBC) testing: within-person day to day variation in a healthy volunteer. Med Res Archives. 2017; 5(9).

26. Price CP. Point of care testing. BMJ. 2001; 322:1285–8.

27. Price CP. Delivering clinical outcomes. Point Care. 2003; 2:151–7.

28. Gialamas A, Yelland LN, Ryan P, Willson K, Laurence CO, Bubner TK, et al. Does point-of-care testing lead to the same or better adherence to medication? A randomised controlled trial: the PoCT in General Practice Trial. Med J Aust. 2009; 191:487–91.

29. Cohen J, Piterman L, McCall LM, Segal L. Near-patient testing for serum cholesterol: attitudes of general practitioners and patients, appropriateness, and costs. Med J Aust. 1998; 168:605–9.

30. Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016; 37:1944–58.

31. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106:3143–421.

32. Martin SS, Blaha MJ, Elshazly MB, Brinton EA, Toth PP, McEvoy JW, et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol. 2013; 62:732–9.

33. Jialal I, Inn M, Siegel D, Devaraj S. Underestimation of low density lipoprotein-cholesterol with the friedewald equation versus a direct homogenous low density lipoprotein-cholesterol assay. Lab Med. 2017; 48:220–4.

34. Mora S, Rifai N, Buring JE, Ridker PM. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem. 2009; 55:888–94.

35. Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011; 4:337–45.

36. Sniderman AD, Islam S, Yusuf S, McQueen MJ. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. Atherosclerosis. 2012; 225:444–9.

37. van Deventer HE, Miller WG, Myers GL, Sakurabayashi I, Bachmann LM, Caudill SP, et al. Non-HDL cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated LDL cholesterol in a dyslipidemic population. Clin Chem. 2011; 57:490–501.